Optimization and validation of a multiplex, electrochemiluminescence-based detection assay for the quantitation of immunoglobulin G serotype-specific antipneumococcal antibodies in human serum

Clinical and Vaccine Immunology

Volumn 16, Issue 3, 2009, Pages 387-396

  Marchese, Rocio D ^a   Puchalski, Derek ^a   Miller, Pamela ^a   Antonello, Joseph ^a   Hammond, Olivia ^a   Green, Tina ^a   Rubinstein, Leonard J ^a   Caulfield, Michael J ^a   Sikkema, Daniel ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BACTERIUM ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BLOOD VOLUME; CHEMOLUMINESCENCE; CHILD; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS REACTION; ELECTROCHEMILUMINESCENCE BASED MULTIPLEX ASSAY; ELECTROCHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; LABORATORY TEST; LIGHT; MAJOR CLINICAL STUDY; MEDICAL TECHNOLOGY; METHODOLOGY; MICROTITER PLATE ASSAY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEROTYPE; SERUM; VALIDATION PROCESS; WORLD HEALTH ORGANIZATION;

ANTIBODIES, BACTERIAL; CROSS REACTIONS; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN G; LUMINESCENT MEASUREMENTS; SENSITIVITY AND SPECIFICITY; SERUM; STREPTOCOCCUS PNEUMONIAE;

EID: 61949238873     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00415-08     Document Type: Article

References (29)

1. Blackburn, G. F., H. P. Shah, J. H. Kenten, J. Leland, R. A. Kamin, J. Link, J. Peterman, M. J. Powell, A. Shah, D. B. Talley, et al. 1991. Electrochemiluminescence detection for development of immunoassays and DNA probe assays for clinical diagnostics. Clin. Chem. 37:1534-1539.
2. CDC. 2000. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Preventing pneumococcal disease among infants and young children. MMWR Recommend. Rep. 49(RR09):1-38.
3. Committee on Issues and Priorities for New Vaccine Development. 1986. New vaccine development establishing priorities, vol. II, appendix D-17, p. 357-375. National Academy Press, Washington, DC.
4. Deaver, D. 1995. A new non-isotopic detection system for immunoassays. Nature (London) 377:758-760.
5. FDA. 2001. Guidance for industry bioanalytical method validation. Food and Drug Administration, Rockville, MD.
6. Fedson, D. S., G. Scott, and J. A. Scott. 1999. The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known. Vaccine 17(Suppl.):S11-S18.
7. Findley, J. W. A., W. C. Smith, and J. W. Lee. 2000. Validation of immunoassay for bioanalysis: a pharmaceutical industry perspective. J. Pharm. Biomed. Anal. 21:1249-1273.
8. Greenwood, B. 1999. The epidemiology of pneumococcal infection in children in the developing world. Philos. Trans. R. Soc. Lond. Ser. B 354:777-785.
9. Guglielmo-Viret, V., and P. Thullier. 2007. Comparison of an electrochemiluminescence assay in plate format over a colorimetric ELISA, for the detection of ricin B chain (RCA-B). J. Immunol. Methods 328:70-78.
10. Haaland, P. D. 1989. Experimental design in biotechnology, p. 37-59. Marcel Dekker, New York, NY.
11. Hausdorff, W. P. 2002. Invasive pneumococcal disease in children: geographic and temporal variations in incidence and serotype distribution. Eur. J. Pediatr. 161(Suppl.):S135-S139.
12. Hausdorff, W. P., J. Bryant, R. Cohen, R. Dagan, M. R. Jacobs, S. L. Kaplan, T. Kilpi, E. L. Lopez, E. O. Mason, Jr., S. I. Pelton, V. Syriopoulou, B. Wynne, and G. Yothers. 2002. Multinational study of pneumococcal serotypes causing acute otitis media in children. Pediatr. Infect. Dis. J. 21:1008-1016.
13. Henckaerts, I., D. Goldblatt, L. Ashton, and J. Poolman. 2006. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin. Vaccine Immunol. 13:356-360.
14. International Conference on Harmonization on the Validation of Analytical Methods. 1994. Validation of analytical procedures: text and methodology Q2(R1). ICH harmonized tripartite guideline. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland.
15. Jódar, L., J. Butler, G. Carlone, R. Dagan, D. Goldblatt, H. Käyhty, K. Klugman, B. Plikaytis, G. Siber, R. Kohberger, I. Chang, and T. Cherian. 2003. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 21:3265-3272.
16. Marchese, R., N. Jain, J. Antonello, L. Mallette, K. Butterfield-Gerson, J. Raab, P. Burke, C. Schulman, A. Adgate, D. Sikkema, and N. Chirmule. 2006. ELISAs for measuring antibodies to pneumococcal polysaccharides for the PNEUMOVAX 23 vaccine: assay operating characteristics and correlation to the WHO international assay. Clin. Vaccine Immunol. 13:905-912.
17. Nahm, M., and D. Goldblatt. 26 November 2002, posting date. Training manual for enzyme linked immunosorbent assay for the quantitation of Streptococcus pneumoniae serotype specific IgG. WHO Pneumococcal Serology Reference Laboratories, London, United Kingdom. http://www.vaccine.uab.edu.
18. Nahm, M., and D. Goldblatt. 26 November 2002, posting date. SOP5: selection of a new lot of enzyme-labeled secondary antibody specific for all human IgG subclasses. In Training manual for enzyme linked immunosorbent assay for the quantitation of Streptococcus pneumoniae serotype specific IgG. WHO Pneumococcal Serology Reference Laboratories, London, United Kingdom. http://www.vaccine.uab.edu.
19. O'Connell, M. A., B. A. Belanger, and P. D. Haaland. 1992. The four parameter logistic model for calibration and assay development. Am. Stat. Assoc. Proc. Biopharm. Section 1992:180-185.
20. Pickering, J. W., T. B. Martis, R. W. Greer, M. C. Schroder, M. E. Astill, C. M. Litwin, S. W. Hildreth, and H. R. Hill. 2002. A multiplexed fluorescent microsphere immunoassay for antibodies to pneumococcal capsular polysaccharides. Am. J. Clin. Pathol. 117:589-596.
21. Pickering, J. W., J. D. Hoopes, M. C. Groll, H. K. Romero, D. Wall, H. Sant, M. E. Astill, and H. R. Hill. 2007. A 22-plex chemiluminescent microarray for pneumococcal antibodies. Am. J. Clin. Pathol. 128:23-31.
22. Plikaytis, B. D., D. Goldblatt, C. Frasch, C. Blondeau, M. J. Bybel, G. S. Giebink, I. Jonsdottir, H. Kayhty, H. B. Konradsen, D. V. Madore, M. H. Nahm, C. A. Schulman, P. F. Holder, T. Lezhava, C. M. Elie, and G. M. Carlone. 2000. An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study. J. Clin. Microbiol. 38:2043-2050.
23. Quataert, S. A., C. S. Kirch, L. J. Quackenbush Wiedl, D. C. Phipps, S. Strohmeyer, C. O. Cimino, J. Skuse, and D. V. Madore. 1995. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin. Diagn. Lab. Immunol. 2:590-597.
24. Quataert, S. A., K. Rittenhouse-Olson, C. S. Kirsch, B. Hu, S. Secor, N. Strong, and D. V. Madore. 2004. Assignment of weight-based antibody units for 13 serotypes to a human antipneumococcal standard reference serum lot 89-S(F). Clin. Diagn. Lab. Immunol. 11:1064-1069.
25. Schlottmann, S. A., N. Jain, N. Chirmule, and M. T. Esser. 2006. A novel chemistry for conjugating pneumococcal polysaccharides to luminex microspheres. J. Immunol. Methods 309:75-85.
26. Shapiro, E. D., and J. D. Clemens. 1984. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann. Intern. Med. 101:325-330.
27. Swanson, S. J., S. J. Jacobs, D. Mytych, C. Shah, S. R. Indelicato, and R. W. Bordens. 1999. Applications for the new electrochemiluminescent (ECL) and biosensor technologies. Dev. Biol. Stand. 97:135-147.
28. Wernette, C. M., C. E. Frasch, D. Madore, G. Carlone, D. Goldblatt, B. Plikaytis, W. Benjamin, S. A. Quataert, S. Hildreth, D. J. Sikkema, H. Käyhty, I. Jonsdottir, and M. H. Nahm. 2003. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin. Diagn. Lab. Immunol. 10:514-519.
29. Whitney, C. G., T. Pilishvili, M. M. Farley, W. Schaffner, A. S. Craig, R. Lynfield, A. C. Nyquist, K. A Gershman, M. Vazquez, N. M Bennett, A. Reingold, A. Thomas, M. P. Glode, E. R. Zell, J. H. Jorgensen, B. Beall, and A. Schuchat. 2006. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 28:1495-1502.